Jun 16, 2025

Featuring perspectives from Dr Virginia F Borges, Ms Jamie Carroll, Mr Ronald Stein and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Role of CDK4/6 Inhibitors in Localized and Metastatic Hormone Receptor (HR)-Positive Breast Cancer (12:49)
• PI3K Inhibition as First-Line Treatment for...

Jun 4, 2025

Featuring perspectives from Dr Ian E Krop and Dr Sara M Tolaney, including the following topics:

• Introduction: Adjuvant CDK4/6 Inhibition (0:00)
• HER2-Positive Disease (11:13)
• PARP Inhibition (27:34)
• Antibody-Drug Conjugates (34:12)
• Up-Front Treatment of HR-Positive Metastatic Disease (46:28)

CME information and select...

May 27, 2025

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics:

• Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00)
  • Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy...

May 19, 2025

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics:

• Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00)
  • Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. 

May 7, 2025

Featuring perspectives from Prof Rebecca A Dent and Dr Nancy U Lin, including the following topics:

• Introduction: A New Paradigm for Triple-Positive Breast Cancer? (0:00)
• CDK4/6 Inhibitors for HR-Positive, HER2-Negative Breast Cancer (10:06)
• Oral Selective Estrogen Receptor Degraders for HR-Positive, HER2-Negative...